头孢匹罗治疗社区获得性肺炎的临床观察  

Clinical Trial of Cefipirome on Community-Acquired Pneumonia

作　　者：张东[1] 薛卉[1] 张妍[1] 宋毅[1] 杨育波[1] 孙莹[1] 

机构地区：[1]天津市海河医院,300051

出　　处：《首都医药》2012年第20期39-41,共3页Capital Medicine

摘　　要：目的研究头孢匹罗治疗社区获得性肺炎(CAP)的临床疗效和安全性。方法 60例CAP患者随机分为试验组和对照组,试验组给予头孢匹罗治疗,对照组给予头孢地嗪治疗,疗程7～14d。结果试验组、对照组临床有效率分别为93.3%和70%,细菌清除率分别为92%和65.2%,两组治疗不良反应均轻微,安全性好。结论头孢匹罗治疗社区获得性肺炎疗效显著,细菌清除率高,优于头孢地嗪。Objective To evaluate the clinical efficacy and safety of Cefipirome in the treatment of community-acquired pneumonia （ CAP ） . Methods 60 patients with CAP were randomly divided into two groups, injective Cefipirome was given in the observed group, cefodizime in the controlled group.The course of treatment was 7 - 14d.Resu Its The clinical effective rate of Cefipirome group was 93.3%; the bacterial clearance rate was 88%. While that of cefodizime group was 60% and 65%.The adverse effects are mild and welltolerated.Conc I us i on Cefipirome is more effective and with high capability of bacteria eradication than cefodizime in treating CAP.

关 键 词：头孢匹罗 头孢地嗪 社区获得性肺炎 

分 类 号：R563.1[医药卫生—呼吸系统]